JENKINTOWN, Pa., March 17 /PRNewswire/ -- Dynamis Therapeutics, Inc. announced the discovery of a new class of compounds that inhibit the production of RAGE, the Receptor for Advanced Glycation End Products (AGEs). Scientists expect that a RAGE inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer's, inflammatory diseases, some cancers, and aging.
A patent has been filed on the discovery.
A team of Dynamis Therapeutics' scientists significantly decreased kidney and retina RAGE in aged rats that were orally dosed with Dynamis Therapeutics' RAGE inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited RAGE in a variety of cells grown in culture.
In a parallel experiment, Dynamis Therapeutics' scientists increased the life span of mice by adding a RAGE inhibitor to their drinking water. The laboratory mice were divided into four groups: a control group treated only with water and three groups treated with varying doses of the RAGE inhibitor. The mice receiving the highest RAGE inhibitor dose lived, on average, 256 days longer than those receiving only water. Longevity increased proportionally with dosage strength.
Commented Dr. Annette Tobia, president and founder of Dynamis Therapeutics, Inc., "We are very excited about these results, since discovering RAGE inhibitors enables Dynamis Therapeutics to develop a treatment for diabetic kidney disease and blindness. Diabetes and its complications have become epidemic, not only in the United States, but worldwide. Retinopathy often leads to blindness. It would be a tremendous advance to eventually have a drug to treat such a serious disease."
Dynamis Therapeutics, Inc., located in Jenkintown, Pennsylvania (http://www.dynamis-therapeutics.com), develops products that treat chronic inflammatory conditions and accelerated aging diseases such as diabetic nephropathy and retinopathy.
Dynamis Therapeutics supports its research, in part, by marketing the MEG 21 product line of anti-aging and anti-wrinkling cosmetic skin care products to dermatologists, plastic surgeons, and aestheticians and by out-licensing the cosmetic applications of its breakthrough technology for fees and royalties.
Dynamis Therapeutics' technology is based on the discovery of an aging/inflammatory pathway that was made by its scientific founders while they were working at the Fox Chase Cancer Center in Philadelphia. The technology is exclusively licensed to Dynamis Therapeutics. Dynamis Therapeutics is presently preparing to file an IND with the FDA for a treatment for inflammation associated with dry eye.
CONTACT: Ginny Simon of Project Marketing, Inc., +1-610-889-2036,
gsimon@projectmarketinginc.com, for Dynamis Therapeutics, Inc.
Web site: http://www.dynamis-therapeutics.com/
